Biocon receives Health Canada approval for Bosaya and Vevzuo, biosimilars to Prolia and Xgeva, on April 3, 2026.
Bosaya treats osteoporosis and bone loss, while Vevzuo treats bone metastasis complications from cancer.
Approval based on comprehensive analytical, nonclinical, and clinical data demonstrating high similarity to reference products.
Products target over 2 million osteoporosis patients and hundreds with bone metastasis annually in Canada.